Correspondence The WHO Director-
sector and those in the intersectoral Prevention of General election ﬁ nale cardiovascular disease
Margaret Chan’s election as the the UN family with the legitimacy with a polypill Director-General of WHO (Nov 18, and mandate, WHO should exercise p 1743)1 raises the question of whether
its interorganisational might to Thomas Gaziano and colleagues
she can deliver in this role. In the improve cooperation in areas (Aug 19, p 679)1 report on the Lancet debate between candidates2
such as joint donor assistance, the usefulness of a multidrug regimen for
she came through as someone multilateral sector-wise approach, prevention of cardiovascular disease cautious, yet keen to use the potential
of corporate skills and the power of initiatives in WHO and other partner we disagree with the drugs chosen to communication. However, it is her organisations, the United Nation’s treat hypertension and to the overall pledge to champion the Bangkok Disaster Assistance Fund, health-
Charter for Health Promotion that security-related issues, outbreak Gaziano and colleagues justify the pitches her against a broad range situations, and disasters. Recent use of a calcium-channel blocker in of objectives; achieving these will examples of disasters, including the treating hypertension by referring to necessitate ensuring the success of 2005 earthquake in Pakistan and the ASCOT-BPLA trial2 which showed WHO’s ongoing global programmes the post-conﬂ ict situations in Iraq that an amlodipine-based regimen with time-bound targets, such as and Afghanistan, emphasise the (amlodipine plus perindopril) was more polio eradication, as well as its County
value that WHO can bring to such eﬀ ective than an atenolol-based one
Cooperation Strategy benchmarks. arrangements and the acceptability it
Given that these hinge on complex has in that role.
Finally, WHO should create the for the drugs chosen for treatment
right intraorganisational synergies to comparison.3 As an additional criticism,
First, the question of prioritising garner the support of countries that even though a possible beneﬁ cial
the sensibilities of the government wish to engage in the normative and eﬀ ect of the calcium-channel blocker over the wellbeing of people
standard-setting terms and assist regimen might be assumed, it would
is crucial. Extrapolated to the others that need to be supported be marginal, because the estimated constitutional context “the organ-
technically, thus creating options for number of patients needed to treat
ization shall not seek or receive country engagement.
A radical reform to address these about 1000. We wonder why, in a cost-
issues seems daunting in view of controlling health policy, a thiazide
organization”, this will entail going the vulnerabilities that resource diuretic was not included. Since there beyond involving international civil constraints bring in their wake. is no evidence to support a greater society and calls for redefinition Ultimately, it might also be a eﬃ
of the intergovernmental agency question of prioritising long-term over thiazides, use of a diuretic instead prerogatives in view of the under-
strategic choices over short-term of a calcium-channel blocker would
gains. The key to the former is cost 10–20 times less.4
WHO’s structure; this will necessitate
ments in health is changing as the drawing more than just the ﬁ ne line centred on a multidrug regimen and not environment gets dominated by between being political,which WHO on a smoking cessation campaign. The market dynamics with liberalisation needs to be,and being politicised, importance of smoking in determining of services traditionally in the public which WHO cannot aﬀ ord to the cardiovascular risk proﬁ le in lower domain. WHO will have to broaden become.
its focus outside the traditional I declare that I have no conﬂ ict of interest. sania@heartﬁ le.org
care provision, rather than in the Heartﬁ le, 1 Park Road, Chak Shahzad, Islamabad,
Submissions should be
The Lancet. WHO 2007–12: the era of Margaret
made via our electronic
Chan. Lancet 2006; 368: 1743.
mortality such as those related to submission system at
Brown H. WHO’s Director-General candidates
respond. Lancet 2006; 368: 1225–28. thelancet/
We declare that we have no conﬂ ict of interest.
www.thelancet.comVol 369 January 20, 2007
Network Terms and Conditions 1. Interpretation 1.1 In this Agreement the following terms and expressions shall have the meanings ascribed to them as stated below: “the Bank” means Ulster Bank Limited, of 11-16 Donegall Square East, Belfast, BT1 5UB. “Account” shall mean any account which the Customer has with the Bank and which it wishes to avail of the service in res
2010 Step Therapy Criteria Effective January 1, 2010 Step Therapy Group Description Step Therapy Criteria Requires member has filled at least a 60-day supply of a step 1 drug (i.e. long-acting beta agonist, Spiriva or inhaled corticosteroid) in the last 120 days before Advair will be covered Requires member must have a documented 60-day trial of either Antabuse or naltrexone before